Related Experiment Video
Updated: Jul 14, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Medullary thyroid cancer treated by capecitabine
Sana Intidhar Labidi1, Gwenaelle Gravis, Carole Tarpin
1Department of Medical Oncology, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, 13009 Marseille, France. labidi@lyon.fnclcc.fr
Abstract:
Medullary thyroid carcinoma with distant metastases is generally incurable, with 20% overall survival at 10 years. The treatment goal is palliative. Chemotherapy has a limited role, with low response rates and high toxicities with the different regimens. Here, we report the case of 64-year-old man with metastatic medullary thyroid carcinoma in progression after primary treatment with cisplatin-doxorubicin. The patient received capecitabine 2000 mg/m total per day x 14 days followed by 1-week rest. He received 41 cycles, and presented prolonged and objective tumor response (30 months), without any toxicity.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
